APPLIED DNA SCIENCES INC (APDN) - Dilution Analysis

10-Q filing | 7.2M shares outstanding

S-1/A filing: This prospectus relates to the resale from time to time by the selling stockholders of up to an aggregate of 18,728,341 shares of common stock of BNB Plus Corp.

8-K filing: Applied DNA Sciences, Inc. entered into securities purchase agreements with accredited investors to sell shares of common stock and warrants in private placement offerings, with expected gross proceeds of approximately $26.8 million. ($26.8M proceeds)

10-Q filing | 1.3M shares outstanding

8-K filing: Stock split 1-for-15 | Outstanding: 6,497,790 → 0

10-Q filing | 6.5M shares outstanding

8-K filing: Stock split 1-for-50 | Outstanding: 54,111,523 → 1

10-Q filing | 54.1M shares outstanding

S-1/A filing: This prospectus relates to the resale from time to time, by the selling stockholders of up to an aggregate of 41,640,625 shares of common stock, which the selling stockholders may acquire upon the exercise of outstanding warrants.

10-K filing | 0.7M shares outstanding

S-1 filing: This prospectus relates to the resale from time to time, by the selling stockholders of up to an aggregate of 41,640,625 shares of common stock which the selling stockholders may acquire upon the exercise of outstanding warrants.

8-K filing: Applied DNA Sciences, Inc. entered into a securities purchase agreement for a registered direct offering and concurrent private placement, issuing shares, pre-funded warrants, and common stock purchase warrants, expecting gross proceeds of approximately $6.5 million before deducting fees. ($6.5M proceeds)

10-Q filing | 10.3M shares outstanding

8-K filing: Applied DNA Sciences, Inc. closed an offering of 9,230,769 units, each consisting of common stock or pre-funded warrants and warrants, at a price of $1.30 per unit (or $1.2999 for units including pre-funded warrants), resulting in gross proceeds of approximately $12 million before deducting fees and expenses. ($12.0M proceeds)

S-1/A filing: The company is offering 5,911,330 units, each unit consisting of one share of common stock, one Series A warrant to purchase one share of common stock, and one Series B warrant to purchase one share of common stock, at the assumed public offering price of $2.03 per unit, which was the last reported sales price of our common stock on The Nasdaq Capital Market on May 23, 2024.

S-1/A filing: The company is offering 5,319,149 units, each unit consisting of one share of common stock, one Series A warrant, and one Series B warrant, at an assumed public offering price of $1.88 per unit, as well as offering shares of common stock underlying the Pre-Funded Warrants, Series A Warrants, Series B Warrants and Placement Agent Warrants.

S-1/A filing: S-1/A filing for up to 12,151,395 Shares of Common Stock Underlying the Pre-Funded Warrants, Series A Warrants, Series B Warrants and Placement Agent Warrants, including an offering of 3,984,064 units at $2.51 per unit, each unit consisting of one share of common stock, one Series A warrant, and one Series B warrant.

S-1/A filing: The company is offering shares of common stock along with Series A and B warrants, as well as pre-funded warrants to certain purchasers, with Craig-Hallum Capital Group LLC and Laidlaw & Company (UK) Ltd. acting as placement agents.

10-Q filing | 1.0M shares outstanding

8-K filing: Stock split 1-for-20 | Outstanding: 16,978,703 → 848,935

S-1 filing: The company is offering common stock, Series A warrants, Series B warrants, pre-funded warrants and placement agent warrants.

8-K filing: Applied DNA Sciences, Inc. amended warrants to purchase shares of its common stock, reducing the exercise price to $0.609 per warrant and extending the expiration date to August 9, 2028, for an aggregate of 3,113,213 warrants held by certain holders.

S-1/A filing: This prospectus relates to the resale from time to time, by the selling stockholders of up to 11,288,122 shares of common stock, which the selling stockholders may acquire upon the exercise of outstanding warrants.

S-1 filing: This S-1 filing details a proposed offering of common stock issuable upon the exercise of common warrants, along with company information, business overview, and associated risk factors.

10-Q filing | 17.0M shares outstanding

8-K filing: Applied DNA Sciences, Inc. entered into a placement agency agreement with Maxim Group LLC for a registered direct public offering of shares and warrants, expecting gross proceeds of approximately $3.4 million before deducting fees and expenses, with the offering expected to close on or about February 2, 2024. ($3.4M proceeds)

10-K filing | 13.1M shares outstanding

10-Q filing | 12.9M shares outstanding

8-K filing: Applied DNA Sciences, Inc. acquired Spindle Biotech Inc. through a Share Purchase Agreement, issuing 750,000 restricted shares of common stock to the sellers as part of the consideration.

S-3 filing: Applied DNA Sciences, Inc. files an S-3 to offer and sell up to $75,000,000 of common stock, preferred stock, debt securities, warrants and rights, or any combination of these securities, and/or units consisting of one or more of these securities.

10-Q filing | 12.9M shares outstanding

10-Q filing | 12.9M shares outstanding

10-K filing | 7.5M shares outstanding

10-Q filing | 9.0M shares outstanding

8-K filing: Applied DNA Sciences, Inc. completed a public offering involving the issuance and sale of 2,820,000 shares of common stock, pre-funded warrants to purchase 180,000 shares of common stock and warrants to purchase 6,000,000 shares of common stock, for net proceeds of approximately $11.1 million.

S-1/A filing: This S-1/A filing includes the offering of common stock, pre-funded warrants, Series A Warrants, and Series B Warrants, with the net proceeds to be used for the further development of their Therapeutic DNA Production and MDx Testing Services, as well as general corporate purposes.

S-3 filing: This prospectus relates to the resale of up to 1,496,400 shares of Applied DNA Sciences, Inc.'s common stock issuable upon the exercise of warrants.

S-1 filing: This S-1 filing highlights information about the company, the offering of common stock, pre-funded warrants, and common warrants, and related documents, but is not complete and does not contain all information to consider before investing.

10-Q filing | 8.1M shares outstanding

8-K filing: Applied DNA Sciences, Inc. entered into a securities purchase agreement for a registered direct offering of 1,496,400 shares of common stock and/or pre-funded warrants, along with unregistered warrants, expecting to receive approximately $4.2 million in gross proceeds. ($4.2M proceeds)

10-Q filing | 7.5M shares outstanding

10-K filing | 6.9M shares outstanding

10-Q filing | 7.5M shares outstanding

10-Q filing | 7.5M shares outstanding

10-Q filing | 7.5M shares outstanding

S-3/A filing: This prospectus relates to the resale by the selling stockholders named herein, including their transferees, pledgees or donees, or their respective successors, of up to 259,000 shares of Applied DNA Sciences, Inc.'s common stock, $.001 par value, issuable upon the exercise of warrants to purchase 259,000 shares of common stock.

S-3 filing: This prospectus relates to the resale of up to 259,000 shares of Applied DNA Sciences, Inc.'s common stock issuable upon the exercise of warrants.

8-K filing: Applied DNA Sciences, Inc. entered into a placement agency agreement with Roth Capital Partners, LLC for a registered direct public offering of 1,810,000 shares of common stock at $8.30 per share, expecting to receive approximately $13,971,390 in aggregate proceeds after deducting Placement Agent fees. ($15.02M proceeds)

10-K filing | 5.7M shares outstanding

8-K filing: Applied DNA Sciences, Inc. entered into Warrant Exercise Agreements with Dillon Hill Capital, LLC and its affiliate, Dillon Hill Investment Company LLC, whereby 318,000 warrants with an exercise price of $5.25 per share of the Company's common stock were exercised, resulting in gross proceeds to the Company of $1,669,500, and the Company issued 159,000 replacement warrants with an exercise price of $7.54. ($1.67M proceeds)

10-Q filing | 5.1M shares outstanding

S-3 filing: Applied DNA Sciences files an S-3 form to register securities for sale, including common stock, preferred stock, and debt securities, with a total offering amount of up to $50,000,000.00.

10-Q filing | 4.7M shares outstanding

10-Q filing | 3.5M shares outstanding